Sarepta Therapeutics, Inc. (SRPT) Stock Analysis 2026
BriMind AI Score
ProprietaryScore based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.
BriMind 1-Year Price Target
An even blend of the BriMind AI model's DCF and momentum target ($15.51) and Wall Street's consensus target ($21.64).
AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics develops treatments for Duchenne muscular dystrophy and other rare neuromuscular diseases. Its portfolio includes exon-skipping RNA therapies that produce partial dystrophin protein in specific genetic subsets of patients, and Elevidys, a gene therapy delivering a shortened dystrophin gene. Sarepta has built deep relationships in the Duchenne community and substantial commercial infrastructure in a small, well-defined patient population.
How Sarepta Therapeutics Makes Money
Revenue comes from marketed products — the exon-skipping therapies and Elevidys — sold at high prices to a small patient population, largely reimbursed by commercial insurers and public payers. The model depends on patient identification, treatment centre capacity for gene therapy administration, and payer willingness to fund very expensive one-time treatments. A collaboration with Roche provides ex-United States commercialisation for Elevidys.
Sarepta Therapeutics Revenue & Profitability Breakdown
This chart shows how Sarepta Therapeutics's revenue flows through to profit. As a financial-sector company, Sarepta Therapeutics doesn't report a traditional cost-of-revenue/gross-margin split, so the cascade starts from operating expenses and works down to net income — the actual profit shareholders own. A high net margin indicates efficient expense control and capital allocation.
Key Financial Metrics
Sarepta Therapeutics, Inc. doesn't carry a meaningful trailing P/E right now, generates $22.1M in free cash flow, runs a debt/equity ratio of 69.54, and converts shareholder equity into profit at a -9.5% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.
Wall Street Analyst Consensus
Wall Street analysts covering Sarepta Therapeutics, Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $22.26 (+30.2% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.
Intrinsic Value Estimates for SRPT
We use 1 valuation model to estimate SRPT's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.
Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.
Technical Price Signals
SRPT is currently in a death cross pattern, trading below its 50-day average of $17.84 and below its 200-day average of $19.11. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.
SRPT Investment Case: Bull vs Bear
SRPT's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.
Bull Case (Reasons to Buy)
- Sarepta holds the leading commercial position in Duchenne muscular dystrophy, with entrenched physician and patient community relationships.
- Elevidys addresses a far broader share of Duchenne patients than exon-skipping therapies, which are limited to specific mutations.
- Rare disease pricing supports substantial revenue from a small patient count, with limited competitive pricing pressure.
- The Roche partnership provides international reach and cost sharing without building global infrastructure.
Bear Case (Key Risks)
- Gene therapy safety events in Duchenne have prompted regulatory scrutiny and label changes, which materially affects uptake and sentiment.
- The clinical benefit of dystrophin expression as a surrogate endpoint has been debated, leaving accelerated approvals exposed to confirmatory trial outcomes.
- The patient population is inherently finite, so revenue growth eventually depends on new indications rather than deeper penetration.
- Competing Duchenne programmes from other developers could take share in a limited population.
What to Watch: SRPT Key Metrics
SRPT Stock — Frequently Asked Questions
Compare SRPT with Peers
More Healthcare Stock Analysis
In-depth reports on companies operating alongside SRPT — business models, bull and bear cases, and the metrics that matter.
Unlock the Full SRPT Analysis
Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.